This is a research study in minorities to compare the outcomes of two procedures that restore blood flow to the arteries of the heart. In one procedure the blockages are ballooned and then stented with a small wire mesh tube through a small incision in the wrist or the groin. The other procedure is an open-heart operation in which healthy blood vessels from inside the chest, leg, and/or forearm are used to "bypass" the blockages (like a detour). Outcomes will be measured by comparing survival and improvement in quality-of-life.THIS STUDY IS ENROLLING BY INVITATION ONLY

The purpose of this study is to evaluate the effect of the Bria-IMT regimen in combination with Check Point Inhibitor (CPI) on overall survival (OS) compared to treatment of physician’s choice (TPC) chemotherapy in patients with metastatic breast cancer with no approved alternative therapies available as per the Inclusion criter                          Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

We are seeking adult males to participate in a study exploring the benefits of exercise on the human skeleton. and bone health. THIS STUDY IS ENROLLING BY INVITATION ONLY -   There will be two groups of participants--tennis players and controls. Tennis players will be identified by sending a recruitment email to members of college tennis teams at the 12 universities and colleges within 1.5 hours drive from Indianapolis. Tennis team members will be identified by viewing publicly posted online rosters. Controls will be recruited by sending an email to undergraduate students enrolled in the departments of kinesiology and health sciences at Indiana University Indianapolis.

The purpose of this study is to collect data on the performance of sensor(s) each connected to/integrated with the transmitter(s) during 7-17 days of wear (approximately 170 to 410 hours) in subjects with type 1 or type 2 diabetes, 2-80 years of age.THIS STUDY IS ENROLLING BY INVITATION ONLY 

Researchers as the Indiana University Simon Comprehensive Cancer Center are conducting a study to research the safety and effectiveness of increasing doses of CD4CAR T cell therapy for patients who have been diagnosed with, or are being treated for, relapsed or refractory (has not responded to treatment) CD4+ chronic myelomonocytic leukemia (CMML).  CD4+ CMML is a blood cancer that affects white blood cells that express the protein CD4. The CD4CAR therapy is designed to bind to and eliminate cells, including cancer cells that have this protein.  We will evaluate up to 5 different dose levels of CD4CAR T cells and study what side effects occur with these dose levels.  We will also evaluate how effective the dose levels are at treating cancer in the participants in this study.  This therapy is considered investigational which means it has not been approved by the Food and Drug Administration (FDA) as treatment for your.  Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.THIS STUDY IS ENROLLING BY INVITATION ONLY